Arş. Gör. Deniz TURAL

Yayın Ağı

Makaleler 35

1. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Güzel H. G., et al.

Journal of Chemotherapy , cilt.37, sa.6, ss.551-562, 2025 (SCI-Expanded)

2. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

EROL C., Yekeduz E., Tural D., Karakaya S., ŞENTÜRK ÖZTAŞ N., Ucar G., et al.

UROLOGIA INTERNATIONALIS , cilt.107, ss.595-601, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

3. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

Yekeduz E., Tural D., Erturk I., Karakaya S., EROL C., Ercelep O., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.148, sa.12, ss.3537-3546, 2022 (SCI-Expanded)

4. The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

Yucel K. B., Yekeduz E., Karakaya S., Tural D., Erturk I., EROL C., et al.

SCIENTIFIC REPORTS , cilt.12, sa.1, 2022 (SCI-Expanded)

5. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study

Hizal M., Bilgin B., Paksoy N., Kilickap S., Atci M. M., KAHRAMAN S., et al.

FUTURE ONCOLOGY , cilt.18, ss.2573-2582, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

6. Crizotinib for c-MET-amplified advanced NSCLC: a single-center experience

Tacar S. Y., Yilmaz M., Oz B., Tural D.

TUMORI JOURNAL , cilt.108, sa.3, ss.258-262, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma

7. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study

Tacar S. Y., Selcukbiricik F., Yilmaz M., Erturk K., Sarici A. M., Gulturk I., et al.

MELANOMA RESEARCH , cilt.31, sa.5, ss.449-455, 2021 (SCI-Expanded)

8. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., et al.

FUTURE ONCOLOGY , cilt.17, sa.35, ss.4861-4869, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

9. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab

Tural D., Olmez O. F., Sumbul A. T., Ozhan N., ÇAKAR B., Kostek O., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.26, ss.1506-1513, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

10. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

Peled N., Gillis R., Kilickap S., Froesch P., Orlov S., Filippova E., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.16, sa.3, 2021 (SCI-Expanded)

11. Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.

Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.6, 2021 (SCI-Expanded)

12. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.6, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

13. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., et al.

LUNG CANCER , cilt.148, ss.48-54, 2020 (SCI-Expanded)

14. Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy

YILDIZ İ., Bilici A., Karadurmus N., Ozer L., Tural D., Kaplan M. A., et al.

TUMORI J , cilt.104, sa.6, ss.444-450, 2018 (SCI-Expanded)

15. Clinical and pathological characteristics and their effect on survival in elderly patients with gastrointestinal stromal tumors

Mandel N. M., Selcukbiricik F., Kanitez M., Yalcin S., Tural D., Erdamar S., et al.

JOURNAL OF BUON , cilt.21, sa.2, ss.360-365, 2016 (SCI-Expanded)

16. Human Papillomavirus in Head and Neck Cancer

Tambas M., Altun M., Tural D.

HUMAN PAPILLOMAVIRUS - RESEARCH IN A GLOBAL PERSPECTIVE , ss.255-288, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma

17. Late relapse of testicular cancer: Recurrence after 24 years and treatment with chemotherapy alone

Akar E., Tural D., Arslan D., BAŞSORGUN C. İ., Yildiz O.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.11, sa.3, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

18. Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer

Arslan D., Tural D., Koca T., Tastekin D., Cerkesli A. K., Basaran H., et al.

JOURNAL OF BUON , cilt.20, sa.2, ss.573-579, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

19. Is Perineural Invasio (PN) a Determinant of Disease Free Survival in Early Stage Colorectal Cancer?

Ozturk M. A., DANE F., Karagoz S., Tural D., Selcukbiricik F., Demirelli F., et al.

HEPATO-GASTROENTEROLOGY , cilt.62, sa.137, ss.59-64, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma

20. Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer

Tural D., Selcukbiricik F., Yildiz O., Elcin O., Erdamar S., Guney S., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.19, sa.5, ss.889-896, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

21. P95 HER2 fragments and breast cancer outcome

Tural D., Akar E., Mutlu H., KILIÇKAP S.

EXPERT REVIEW OF ANTICANCER THERAPY , cilt.14, sa.9, ss.1089-1096, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

22. Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma

Tural D., Akar E., Ozturk M. A., Yildiz O., Turna H., Serdengecti S.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.10, sa.3, ss.745-748, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

23. Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

Tural D., Batur S., Erdamar S., Akar E., Kepil N., Mandel N. M., et al.

TUMOR BIOLOGY , cilt.35, sa.2, ss.1041-1049, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

24. Cancer Pain Prevalence and its Management

Arslan D., Koca T., Akar E., Tural D., Ozdogan M.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.20, ss.8557-8562, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

25. PET-CT changes the management and improves outcome in patients with recurrent colorectal cancer

Tural D., Selcukbiricik F., Sager S., Akar E., Yildiz O., Serdengecti S.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.10, sa.1, ss.121-126, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma

26. Herbal Administration and Interaction of Cancer Treatment

Arslan D., Tural D., Akar E.

JOURNAL OF PALLIATIVE MEDICINE , cilt.16, sa.11, ss.1466-1476, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

27. Gastric cancer: A case study in Turkey

Tural D., Selcukbiricik F., Akar E., Serdengecti S., Buyukunal E.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.9, sa.4, ss.644-648, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

28. The Relation between Pathological Complete Response and Clinical Outcome in Patients with Rectal Cancer

Tural D., Selcukbiricik F., Ozturk M. A., Yildiz O., Turna H., Er-damar S., et al.

HEPATO-GASTROENTEROLOGY , cilt.60, sa.126, ss.1365-1370, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

29. Association KRAS G13D Tumor Mutated Outcome in Patients with Chemotherapy Refractory Metastatic Colorectal Cancer Treated with Cetuximab

Tural D., Selcukbiricik F., Erdamar S., Ozkurt C. U., Yanmaz T., Mandel N. M., et al.

HEPATO-GASTROENTEROLOGY , cilt.60, sa.125, ss.1035-1040, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

30. Male Breast Cancer: 37-Year Data Study at a Single Experience Center in Turkey

Selcukbiricik F., Tural D., Aydogan F., Bese N., Buyukunal E., Serdengecti S.

JOURNAL OF BREAST CANCER , cilt.16, sa.1, ss.60-65, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

31. Gastrointestinal Stromal Tumors in Turkey: Experiences from 3 Centers

Selcukbiricik F., Yalcin S., Tural D., Erdamar S., Demir G., Dogusoy G., et al.

ONKOLOGIE , cilt.36, ss.18-24, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

32. Male Breast Cancers Behave Differently in Elderly Patients

Tural D., Selcukbiricik F., Aydogan F., Bese N., Yetmen O., Ilvan S., et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY , cilt.43, sa.1, ss.22-27, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

33. A comparison of patient characteristics, prognosis, treatment modalities, and survival according to age group in gastric cancer patients

Tural D., Selcukbiricik F., Serdengecti S., Buyukunal E.

WORLD JOURNAL OF SURGICAL ONCOLOGY , cilt.10, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

34. Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.

HIZ V. M. M., Tural ., Molinas M. N., Dervisoglu ., Dincbas F ., Koca ., et al.

Jpn J Clin Oncol , cilt.420-6, ss.1093, 2012 (Hakemli Dergi)

35. Perineural Invasion Independent Prognostic Factors in Patients with Gastric Cancer Undergoing Curative Resection

Selcukbiricik F., Tural D., Buyukual E., Serdengecti S.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.13, sa.7, ss.3149-3152, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 8

1. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience

Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38, (Özet Bildiri)

2. Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: Two Turkish hospital experience, a retrospective comparative case series study

Ekenel M., Aydın E., CIL I., ZIRTILOGLU A., TURAL D., KARABULUT S.

42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, cilt.28, (Özet Bildiri)

3. Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial.

Yildiz I., Ekenel M., Altman T., KOCAR M., Uysal M., Kanitez M., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)

4. Metastatik berrak hücreli dışı kanserde sunitinib tedavisinin etkinliği ve tosisitesi: Çok merkezli retrospektif TOG çalışması

YILDIZ İ., EKENEL M., AKMAN T., KOCAR M., UYSAL M., KANITEZ M., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 19 - 23 Mart 2014, ss.326-327, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

5. ANTİ-VEGF TKİ VERİLEN BEYİN METASTAZLI RENAL HÜCRELİ KANSER OLGULARINDA KLİNİK SONUÇLAR VE PROGNOSTİK FAKTÖRLER: ÇOK MERKEZLİ TOG ÇALIŞMASI İLK SONUÇLARI

YILDIZ I., EKENEL M., AKMAN T., BAYOGLU I. V., TURAL D., YAZICI O., et al.

5. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 19 - 23 Mart 2014, ss.549, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

6. Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer.

Bilici A., Selcukbiricik F., Ustaalioglu B. B. O., Tural D., Seker M., Gumus M., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri) Sürdürülebilir Kalkınma